Atty. Dkt. No. 065691-0179

Application No. 09/462,909

or ochoslos

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A composition comprising the peptide:

wherein Y and Z consist of: comprise:

- (a) amino acid chains consisting of 0-6 amino acids; or
- (b) chains of compounds which are not amino acids,

wherein A_1 and A_2 are amino acid sequences consisting of comprising 1 to 5 amino acids (SEQ ID NOS: 97-168) and further wherein the peptide is not selected from the group consisting of one of the following sequences:

- -W-S-P-C-S-V-T-C-G- (SEQ ID NO:2),
- -W-S-S-C-S-V-T-C-G- (SEQ ID NO:3), and
- -W-S-Q-C-S-V-T-C-G- (SEQ ID NO:4).
- 2. (Currently amended) The composition according to claim 1, wherein said A₁ is Pro or -X₁-W-X₂-X₃-(SEQ ID NO:5), -X₁, -X₂, and -X₃ being chosen, independently of each other, from G, S and C, denoted SEQ ID NOS:50-59.
- 3. (Currently amended) The composition according to claim 2, wherein said A₁ is -X₁-W-S-X₃-(SEQ ID NO:6). , denoted SEQ ID NOS:60-64.
- 4. (Currently amended) The composition according to claim 1, wherein said A₂ is selected from the group consisting of -R-S-, -V-S-, and -V-T-, -, denoted SEQ-ID NOS:65-88.
- 5. (Currently amended) The composition according to claim 3, wherein said peptide is the following amino acid sequence: -W-S-X₁-W-S-X₃-C-S- A₂-C-G- (SEQ ID NOS:7), denoted SEQ ID NOS:7 and SEQ ID NOS:89 96, wherein, X₁ and X₃-are independently selected from G, S and C.

6. (Currently amended) The composition according to claim 4, wherein said peptide is the following amino acid sequence:

- 7. (Canceled)
- ** (Previously presented) A composition comprising a peptide according to claim 1 and a pharmaceutically acceptable vehicle.
 - 9 12. (Canceled)
- (Previously presented) An additive for culturing nerve cells, comprising a peptide according to claim 1.
 - 14. (Canceled)
 - 15. (Canceled)
- 14. 16. (Currently amended) A peptide consisting of having the following amino acid sequence:

- 19 19. (Previously presented) A composition comprising a peptide according to claim 16 and a pharmaceutically acceptable vehicle.
 - 18. (Canceled)
 - 19-21. (Canceled)
- 16 22. (Previously presented) An additive for culturing nerve cells, comprising a peptide according to claim 16.14
 - 23. (Canceled)
- q. 24. (New) A composition according to claim 1, wherein the peptide is selected from the group consisting of SEQ ID NOS: 97-168.

- $10 \cdot 25$. (New) A composition according to claim 2, wherein the peptide is selected from the group consisting of SEQ ID NOS: 50-59.
- (New) A composition according to claim 3, wherein the peptide is selected from the group consisting of SEQ ID NOS: 60-64.
- 19. 27. (New) A composition according to claim 4, wherein the peptide is selected from the group consisting of SEQ ID NOS: 65-88.
- $3 \cdot 28$. (New) A composition according to claim 5, wherein the peptide is selected from the group consisting of SEQ ID NOS: 89-96.